Identification | Back Directory | [Name]
2-[(4-Cyanophenyl)amino]-N-[4-(4-fluorophenyl)-3-pyridinyl]-4-pyrimidinecarboxamide | [CAS]
2227279-84-5 | [Synonyms]
GSK-3 inhibitor 3 2-[(4-Cyanophenyl)amino]-N-[4-(4-fluorophenyl)-3-pyridinyl]-4-pyrimidinecarboxamide | [Molecular Formula]
C23H15FN6O | [MOL File]
2227279-84-5.mol | [Molecular Weight]
410.4 |
Chemical Properties | Back Directory | [density ]
1.41±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
10.33±0.70(Predicted) | [color ]
Off-white to light yellow |
Hazard Information | Back Directory | [Uses]
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC50s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research[1]. | [IC 50]
GSK-3α: 0.35 nM (IC50); GSK-3β: 0.25 nM (IC50); CDK2: 0.22 μM (IC50); CDK5: 1.3 μM (IC50) | [References]
[1] Hartz RA, et.al. Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors. J Med Chem. 2023 Jun 8;66(11):7534-7552. DOI:10.1021/acs.jmedchem.3c00364 |
|
|